Anales RANF

Juan Aparicio Blanco, Ignacio A. Romero, Jean P Benoit, Ana I. Torres Suárez @Real Academia Nacional de Farmacia. Spain 212 21. Esposito E, Drechsler M, Cortesi R, Nastruzzi C. Encapsulation of cannabinoid drugs in nanostructured lipid carriers. European Journal of Pharmaceutics and Biopharmaceutics. 2016;102:87-91. 22. Linsell O, Brownjohn PW, Nehoff H, Greish K, Ashton JC. Effect of styrene maleic acid WIN55,212- 2 micelles on neuropathic pain in a rat model. Journal of Drug Targeting. 2015;23:353-9. 23. He XL, Yang L, Wang M, Zhuang XZ, Huang RQ, Zhu RR, et al. Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles. Cellular Physiology and Biochemistry. 2017;42:2281- 94. 24. Berrocoso E, Rey-Brea R, Fernandez-Arevalo M, Mico JA, Martin-Banderas L. Single oral dose of cannabinoid derivate loaded PLGA nanocarriers relieves neuropathic pain for eleven days. Nanomedicine-Nanotechnology Biology and Medicine. 2017;13:2623-32. 25. Duran-Lobato M, Martin-Banderas L, Goncalves LMD, Fernandez-Arevalo M, Almeida AJ. Comparative study of chitosan- and PEG-coated lipid and PLGA nanoparticles as oral delivery systems for cannabinoids. Journal of Nanoparticle Research. 2015;17:17. 26. Martin-Banderas L, Alvarez-Fuentes J, Duran-Lobato M, Prados J, Melguizo C, Fernandez-Arevalo M, et al. Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies. International Journal of Nanomedicine. 2012;7:5793-806. 27. Duran-Lobato M, Martin-Banderas L, Lopes R, Goncalves LMD, Fernandez-Arevalo M, Almeida AJ. Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility. Drug Development and Industrial Pharmacy. 2016;42:190-8. 28. Sweeney MD, Sagare AP, Zlokovic BV. Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nature Reviews Neurology. 2018;14:133-50. 29. Sarkaria JN, Hu LS, Parney IF, Pafundi DH, Brinkmann DH, Laack NN, et al. Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology. 2018;20:184-91. 30. Bertrand N, Wu J, Xu XY, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Advanced Drug Delivery Reviews. 2014;66:2-25. 31. Oller-Salvia B, Sanchez-Navarro M, Giralt E, Teixido M. Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery. Chemical Society Reviews. 2016;45:4690-707. 32. Peluffo H, Unzueta U, Negro-Demontel ML, Xu ZK, Vaquez E, Ferrer-Miralles N, et al. BBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNS. Biotechnology Advances. 2015;33:277-87. 33. Laprairie RB, Bagher AM, Kelly MEM, Denovan- Wright EM. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. British Journal of Pharmacology. 2015;172:4790-805. 34. Martinez-Pinilla E, Varani K, Reyes-Resina I, Angelats E, Vincenzi F, Ferreiro-Vera C, et al. Binding and Signaling Studies Disclose a Potential Allosteric Site for Cannabidiol in Cannabinoid CB2 Receptors. Frontiers in Pharmacology. 2017;8:10. 35. Espejo-Porras F, Fernandez-Ruiz J, Pertwee RG, Mechoulam R, Garcia C. Motor effects of the non- psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors. Neuropharmacology. 2013;75:155-63. 36. Nabissi M, Morelli MB, Amantini C, Liberati S, Santoni M, Ricci-Vitiani L, et al. Cannabidiol stimulates Aml-1a-dependent glial differentiation and inhibits glioma stem-like cells proliferation by inducing autophagy in a TRPV2-dependent manner. International Journal of Cancer. 2015;137:1855-69. 37. Xiong W, Cui TX, Cheng KJ, Yang F, Chen SR, Willenbring D, et al. Cannabinoids suppress inflammatory and neuropathic pain by targeting alpha 3 glycine receptors. Journal of Experimental Medicine. 2012;209:1121-34. 38. Mecha M, Feliu A, Inigo PM, Mestre L, Carrillo- Salinas FJ, Guaza C. Cannabidiol provides long- lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A(2A) receptors. Neurobiology of Disease. 2013;59:141-50. 39. Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proceedings of the National Academy of Sciences of the United States of America. 2013;110:5193-8. 40. Seeman P. Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. Translational Psychiatry. 2016;6:e920. 41. Wu XY, Han LJ, Zhang XL, Li L, Jiang CZ, Qiu Y, et al. Alteration of endocannabinoid system in human gliomas. Journal of Neurochemistry. 2012;120:842-9. 42. Andradas C, Caffarel MM, Perez-Gomez E, Salazar M, Lorente M, Velasco G, et al. The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK. Oncogene. 2011;30:245-52. 43. Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: A new platform for nanomedicine. International Journal of Pharmaceutics. 2009;379:201- 9.